Stopdapt 2 randomized clinical trial

Effect of 1-Month Dual Antiplatelet Therapy Followed
by Clopidogrel vs 12-Month Dual Antiplatelet Therapy
onCardiovascularandBleedingEventsinPatientsReceivingPCI
The STOPDAPT-2 Randomized Clinical Trial
Hirotoshi Watanabe, MD; Takenori Domei, MD; Takeshi Morimoto, MD; Masahiro Natsuaki, MD; Hiroki Shiomi, MD; Toshiaki Toyota, MD;
Masanobu Ohya, MD; Satoru Suwa, MD; Kensuke Takagi, MD; Mamoru Nanasato, MD; Yoshiki Hata, MD; Masahiro Yagi, MD; Nobuhiro Suematsu, MD;
Takafumi Yokomatsu, MD; Itaru Takamisawa, MD; Masayuki Doi, MD; Toshiyuki Noda, MD; Hideki Okayama, MD; Yoshitane Seino, MD;
Tomohisa Tada, MD; Hiroki Sakamoto, MD; Kiyoshi Hibi, MD; Mitsuru Abe, MD; Kazuya Kawai, MD; Koichi Nakao, MD; Kenji Ando, MD; Kengo Tanabe, MD;
Yuji Ikari, MD; Keiichi Igarashi Hanaoka, MD; Yoshihiro Morino, MD; Ken Kozuma, MD; Kazushige Kadota, MD; Yutaka Furukawa, MD;
Yoshihisa Nakagawa, MD; Takeshi Kimura, MD; for the STOPDAPT-2 Investigators
IMPORTANCE Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI) with a drug-eluting stent may be an attractive option.
OBJECTIVE To test the hypothesis of noninferiority of 1 month of DAPT compared with
standard 12 months of DAPT for a composite end point of cardiovascular and bleeding events.
DESIGN, SETTING, AND PARTICIPANTS Multicenter, open-label, randomized clinical trial
enrolling 3045 patients who underwent PCI at 90 hospitals in Japan from December 2015
through December 2017. Final 1-year clinical follow-up was completed in January 2019.
INTERVENTIONS Patients were randomized either to 1 month of DAPT followed by clopidogrel
monotherapy (n=1523) or to 12 months of DAPT with aspirin and clopidogrel (n=1522).
MAIN OUTCOMES AND MEASURES The primary end point was a composite of cardiovascular
death, myocardial infarction (MI), ischemic or hemorrhagic stroke, definite stent thrombosis,
or major or minor bleeding at 12 months, with a relative noninferiority margin of 50%.
The major secondary cardiovascular end point was a composite of cardiovascular death,
MI, ischemic or hemorrhagic stroke, or definite stent thrombosis and the major secondary
bleeding end point was major or minor bleeding.
RESULTS Among 3045 patients randomized, 36 withdrew consent; of 3009 remaining, 2974
(99%) completed the trial. One-month DAPT was both noninferior and superior to 12-month
DAPT for the primary end point, occurring in 2.36% with 1-month DAPT and 3.70% with
12-month DAPT (absolute difference, −1.34% [95% CI, −2.57% to −0.11%]; hazard ratio [HR],
0.64 [95% CI, 0.42-0.98]), meeting criteria for noninferiority (P < .001) and for superiority
(P = .04). The major secondary cardiovascular end point occurred in 1.96% with 1-month
DAPT and 2.51% with 12-month DAPT (absolute difference, −0.55% [95% CI, −1.62% to
0.52%]; HR, 0.79 [95% CI, 0.49-1.29]), meeting criteria for noninferiority (P = .005) but not
for superiority (P = .34). The major secondary bleeding end point occurred in 0.41% with
1-month DAPT and 1.54% with 12-month DAPT (absolute difference, −1.13% [95% CI, −1.84%
to −0.42%]; HR, 0.26 [95% CI, 0.11-0.64]; P = .004 for superiority).
CONCLUSIONS AND RELEVANCE Among patients undergoing PCI, 1 month of DAPT followed
by clopidogrel monotherapy, compared with 12 months of DAPT with aspirin and clopidogrel,
resulted in a significantly lower rate of a composite of cardiovascular and bleeding events,
meeting criteria for both noninferiority and superiority. These findings suggest that a shorter
duration of DAPT may provide benefit, although given study limitations, additional research is
needed in other populations.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02619760
JAMA. 2019;321(24):2414-2427. doi:10.1001/jama.2019.8145
Editorial page 2409
Related article page 2428
Audio and Supplemental
content
CME Quiz at
jamanetwork.com/learning
Author Affiliations: Author
affiliations are listed at the end of this
article.
Group Information: The
STOPDAPT-2 Investigators are listed
in eAppendix 1 in Supplement 1.
Corresponding Author: Takeshi
Kimura, MD, Department of
Cardiovascular Medicine, Kyoto
University Graduate School of
Medicine, 54 Shogoin Kawahara-cho,
Sakyo-ku, Kyoto, 606-8507 Japan
(taketaka@kuhp.kyoto-u.ac.jp).
Research
JAMA | Original Investigation
2414 (Reprinted) jama.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ AIIMS – Bhubaneswar by Ramachandra Barik on 06/30/2019

T
he optimal duration of dual antiplatelet therapy
(DAPT) after percutaneous coronary intervention
(PCI) using drug-eluting stents is still under debate.
The current US and European guidelines recommend DAPT
for at least 12 months in acute coronary syndrome and for at
least 6 months in stable coronary artery disease without
high bleeding risk.1,2
In a meta-analyses of randomized trials
comparing short (≤6 months) vs prolonged (≥12 months)
DAPT duration, short DAPT was associated with lower
bleeding risk without a significant increase in ischemic
risk.3,4
Furthermore, there is lingering concern about data
suggesting increased mortality with prolonged DAPT.4,5
The introduction of second-generation and newer drug-
eluting stents has markedly decreased the incidence of
stent thrombosis, and widespread acceptance of optimal
medical therapy, statins in particular, has reduced the
incidence of myocardial infarction (MI) unrelated to the
stent.6-9
Therefore, it is becoming increasingly important to
avoid bleeding events because the mortality associated
with a bleeding event has been reported to be comparable
with that of MI.10,11
In this context, very short DAPT duration
after drug-eluting stent implantation may be an attractive
option if it is not associated with an increase in cardiovascu-
lar events disproportionate to the reduction in bleeding
events. In the STOPDAPT (Short and Optimal Duration of
Dual Antiplatelet Therapy After Everolimus-Eluting Cobalt-
Chromium Stent) trial, the incidence of adverse events asso-
ciated with 3 months of DAPT followed by aspirin mono-
therapy after implantation of a polymer-based drug-eluting
stent with small late lumen loss was acceptable compared
with the performance goal based on a historical control.12
Given the very low rate of stent thrombosis with new-
generation drug-eluting stents, the hypothesis of this study
was that further shortening of the mandatory DAPT duration
could be possible without increasing cardiovascular events.
Therefore, the present study sought to explore the efficacy
of 1 month of DAPT compared with the standard of 12
months of DAPT after cobalt-chromium everolimus-eluting
stent (CoCr-EES) implantation.
Methods
Study Design and Population
The STOPDAPT-2 trial was a multicenter, open-label,
adjudicator-blinded randomized clinical trial in Japan
designed to compare 1 month of DAPT with 12 months of
DAPT after CoCr-EES implantation. This study was con-
ducted in accordance with the Declaration of Helsinki and
the Ethical Guidelines for Medical and Health Research
Involving Human Subjects in Japan.13
The ethical committee
in each participating center approved the study protocol.
The protocol and statistical analysis plan are available in
Supplement 2. We screened patients who underwent suc-
cessful PCI with CoCr-EES (Xience Series, Abbott Vascular)
without concomitant use of other types of drug-eluting stent
or in-hospital major complications other than periprocedural
MI. We chose CoCr-EES as the drug-eluting stent type in the
present study because of its thromboresistance demon-
strated in the experimental model and the consistently low
rates of stent thrombosis in previous studies.12,14,15
Exclusion criteria were need for oral anticoagulation or
antiplatelet therapy other than aspirin and P2Y12 receptor
blockers, history of intracranial bleeding, and known intoler-
ance to clopidogrel. Patients with scheduled staged PCI were
to be enrolled after completion of all procedures. Before hos-
pital discharge after the index PCI, eligible patients who pro-
vided written informed consent were randomly assigned in a
1-to-1 ratio either to the experimental group of 1 month of
DAPT followed by clopidogrel monotherapy or to the control
group of 12 months of DAPT with aspirin and clopidogrel,
which was the standard antiplatelet regimen after drug-
eluting stent implantation in patients with both stable coro-
nary artery disease and acute coronary syndrome in Japan.16
Randomization was performed centrally through the elec-
tronic data capture system with a stochastic minimization
algorithm to balance treatment assignment within centers.
Twenty percent of patients were randomly selected for
angiographic analysis in the core laboratory (Cardio Core
Japan, Tokyo). The angiographic core laboratory calculated a
SYNTAX (Synergy Between Percutaneous Coronary Inter-
vention With Taxus and Cardiac Surgery) score, which indi-
cated the degree of coronary anatomic complexity, ranged
from 0 to greater than 50 for very complex lesions, and cat-
egorized patients as having low (≤22), intermediate (23-32),
and high (≥33) coronary anatomic complexity.17
The statisti-
cian, independent clinical event committee, steering com-
mittee, and sponsor (Abbott Vascular) were blinded to study
group assignments. A complete list of the study organiza-
tion, participating centers, and investigators is available in
eAppendix 1 in Supplement 1.
Antiplatelet Regimen
One-month DAPT regimens (given between 30 and 59
days after PCI) were either aspirin, 81 to 200 mg/d, and clopi-
dogrel, 75 mg/d, or aspirin, 81 to 200 mg/d, and prasugrel,
Key Points
Question In patients undergoing percutaneous coronary
intervention, is 1 month of dual antiplatelet therapy (DAPT)
followed by clopidogrel monotherapy noninferior to 12 months
of DAPT with aspirin and clopidogrel for adverse cardiovascular
and bleeding events?
Findings In this randomized clinical trial that included 3045
patients, the 1-year cumulative incidence of a composite end
point consisting of cardiovascular death, myocardial
infarction, ischemic or hemorrhagic stroke, definite stent
thrombosis, and major bleeding was 2.4% in the 1-month DAPT
group and 3.7% in the 12-month DAPT group, a difference
that met the noninferiority margin of a hazard ratio of 0.5,
as well as superiority.
Meaning These findings suggest that 1 month of DAPT followed
by clopidogrel monotherapy provided benefit compared with
12 months of DAPT, although additional research is needed
in other populations.
Effect of 1- vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in PCI Original Investigation Research
jama.com (Reprinted) JAMA June 25, 2019 Volume 321, Number 24 2415

3.75 mg/d, at the discretion of the attending physician. After
hospital discharge, antiplatelet agents were to be prescribed
not by referring practitioners but by the physicians at the par-
ticipating centers. At 1 month, patients in the experimental
group were to stop aspirin and receive clopidogrel mono-
therapy for up to 5 years, while patients in the control group
were to receive DAPT with aspirin and clopidogrel for up to 12
months. For patients who had received prasugrel, prasugrel
was switched to clopidogrel at 1 month in both groups. At 12
months (between 335 and 394 days), patients in the control
group were to stop clopidogrel and receive aspirin mono-
therapy for up to 5 years. Clopidogrel was chosen as mono-
therapy after stopping DAPT at 1 month in the 1-month DAPT
group because in the planning stage of this study in 2015,
many investigators were concerned about a possible increase
of stent thrombosis with very short DAPT duration, and use
of a P2Y12 receptor blocker, which was demonstrated to be
the key drug for prevention of stent thrombosis, might ame-
liorate any increase in stent thrombosis.18,19
Furthermore,
stopping aspirin might be associated with lower risks of gas-
trointestinal and intracranial bleeding, and use of a more
potent antiplatelet agent might make use of aspirin no longer
necessary.20,21
Persistent DAPT discontinuation was defined
as discontinuation of either aspirin or P2Y12 receptor block-
ers according to the study protocol or discontinuation lasting
more than 60 days.
End Points
The primary end point was a composite of cardiovascular
and bleeding events (cardiovascular death, MI, definite
stent thrombosis, ischemic or hemorrhagic stroke, or
Thrombolysis in Myocardial Infarction [TIMI] major or
minor bleeding).22
The major secondary end points
included the cardiovascular end point (a composite of car-
diovascular death, MI, definite stent thrombosis, or ische-
mic or hemorrhagic stroke) and the bleeding end point
(TIMI major or minor bleeding). Myocardial infarction and
stent thrombosis were defined by Academic Research Con-
sortium criteria.23
TIMI major bleeding included intracranial
bleeding, a decrease in hemoglobin concentration of at least
5 g/dL, or an absolute decrease in hematocrit of at least 15%.
TIMI minor bleeding included a decrease in hemoglobin
concentration of at least 3 g/dL or an absolute decrease in
hematocrit of at least 10% when blood loss was observed
and a decrease in hemoglobin concentration of at least 4
g/dL or an absolute decrease in hematocrit of at least 12%
when no blood loss was observed.22
Other prespecified sec-
ondary end points included all-cause death, death due to
cardiovascular cause, MI, definite stent thrombosis, definite
or probable stent thrombosis, ischemic or hemorrhagic
stroke, TIMI major bleeding, TIMI minor bleeding, Bleeding
Academic Research Consortium (BARC)24
type 3 or 5 bleed-
ing, BARC type 5 bleeding, BARC type 3 bleeding, Global Use
of Strategies to Open Occluded Arteries (GUSTO)25
moderate
or severe bleeding, GUSTO severe bleeding, GUSTO moder-
ate bleeding, gastrointestinal bleeding, any coronary revas-
cularization, target lesion revascularization (TLR), clinically
driven TLR, non-TLR coronary revascularization, coronary
artery bypass graft surgery, a composite of death or MI, a
composite of cardiovascular death or MI, and major adverse
cardiac events (a composite of cardiac death, MI, and clini-
cally driven TLR). In addition, post hoc secondary end
points included death due to a cardiac cause, death due to a
noncardiovascular cause, large MI (creatine kinase MB ≥10
times the upper limit of normal), small MI (creatine kinase
MB <10 times the upper limit of normal), MI without cre-
atine kinase MB elevation (troponin positive), MI without
measurement of creatine kinase MB, ischemic stroke, hem-
orrhagic stroke, and intracranial bleeding. The definitions of
clinical end points are described in eAppendix 2 in Supple-
ment 1. Follow-up was commenced at randomization, with
time interval indicated by date of index PCI. All end points
were assessed at 12 months (between 335 and 394 days),
with censoring on day 366. All clinical events comprising
the primary end points were adjudicated based on source
documents by the independent clinical event committee
blinded to randomized treatment group.
Statistical Analysis
The primary hypothesis of this study was that the experi-
mental group (1-month DAPT) was noninferior to the
control group (12-month DAPT) in terms of the primary end
point at 1 year. In the original protocol (June 25, 2015),
a sample size of 2730 patients was calculated assum-
ing a 4.4% estimated event rate (the 80% upper limit of the
confidence interval of 4.0% event rate in the RESET trial),16
setting a noninferiority margin of 2.2% (50% of the esti-
mated event rate) with a power of 80% and a 1-sided
α = .025. In a discussion among the investigators for institu-
tional review board review, the estimated event rate was set
at 4.6% (the 90% upper limit of the confidence interval of
4.0% in the RESET trial), and the noninferiority margin was
set at 2.3% (50% of the estimated event rate). As a result,
the recalculated sample size was 2980 with a power of 85%
and a 1-sided α = .025 (October 11, 2015). On May 30, 2017,
the noninferiority margin was changed again, from an abso-
lute noninferiority margin of 2.3% to a relative margin of
50% on the hazard ratio (HR) scale, to avoid making the
margin too large in case of a lower-than-expected actual
event rate. The relative noninferiority margin of 50% was
chosen considering the feasibility of patient enrollment and
the margins adopted in previous major trials.26,27
If noninferiority was demonstrated, superiority analysis
for the primary end point was to follow. Patients were ana-
lyzed according to their randomization group after excluding
patients who withdrew consent during follow-up (the
intention-to-treat population). Patients with missing out-
come data were censored at the time of loss to follow-up. We
also performed analyses in the per-protocol and as-treated
populations, which were defined as patients continuing the
randomized antiplatelet regimen on day 60 excluding and
including, respectively, those with protocol violations for
inclusion criteria. In addition, we performed a sensitivity
analysis assuming that patients lost to follow-up in the
1-month DAPT group had a primary end point event, while
those in the 12-month DAPT group did not have an event.
Research Original Investigation Effect of 1- vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in PCI
2416 JAMA June 25, 2019 Volume 321, Number 24 (Reprinted) jama.com

We performed subgroup analyses with interaction tests in
the prespecified clinically relevant subgroups, including age
75 years or older, acute coronary syndrome, ST-segment
elevation myocardial infarction, severe chronic kidney dis-
ease, diabetes, total stent length of 28 mm or longer, and 2
or more target vessels, and in post hoc subgroups based on
the Patterns of Non-Adherence to Anti-Platelet Regimen in
Stented Patients (PARIS) thrombotic/bleeding risk scores
and Coronary Revascularization Demonstrating Outcome
Study in Kyoto (CREDO-Kyoto) thrombotic/bleeding risk
scores.28,29
The PARIS thrombotic risk score incorporates 6
factors including diabetes, acute coronary syndrome, cur-
rent smoking, creatinine clearance less than 60 mL/min,
prior PCI, and prior coronary artery bypass graft surgery.
The scores range from 0 to 10, and patients are grouped
according to low (0-2), intermediate (3 or 4), or high (≥5)
thrombotic risk. The PARIS bleeding risk score incorporates
6 factors including age, body mass index, current smoking,
anemia, creatinine clearance less than 60mL/min, and triple
antithrombotic therapy at discharge. The scores range from
0 to 14, with patients categorized as having low (0-3), inter-
mediate (4-7), or high (≥8) bleeding risk. The CREDO-Kyoto
thrombotic risk score incorporates 8 factors including
severe chronic kidney disease, atrial fibrillation, peripheral
vascular disease, anemia, age, heart failure, diabetes, and
chronic total occlusion. The scores range from 0 to 12,
with patients categorized as having low (0-1), intermediate
(2-3), or high (≥4) thrombotic risk. The CREDO-Kyoto bleed-
ing risk score incorporates 7 factors including thrombocyto-
penia, severe chronic kidney disease, peripheral vascular
disease, heart failure, prior MI, malignancy, and atrial fibril-
lation. The scores range from 0 to 11, with patients catego-
rized as having low (0), intermediate (1-2), or high (≥3)
bleeding risk.
We conducted a noninferiority analysis (followed by a su-
periority analysis if noninferiority was met) for the major sec-
ondary cardiovascular end point and superiority analyses for
the other 35 secondary end points. Because of the potential
fortypeIerrorduetomultiplecomparisons,findingsforanaly-
ses of secondary end points should be interpreted as explor-
atory. Landmark analyses at 30 days and 60 days after the in-
dex PCI were also performed for all end points. As a post hoc
analysis, a mixed-effects model was also constructed with site
as a random effect for the primary end point.
Categorical variables were expressed as frequency
and percentage, and continuous variables were expressed as
mean with standard deviation or median with interquartile
range depending on the distribution. Patients with mis-
sing values for clinical characteristics other than left
ventricular ejection fraction less than 40% were regarded as
not having these characteristics. We did not perform impu-
tation for missing values for left ventricular ejection frac-
tion. The proportion of patients with persistent DAPT dis-
continuation and cumulative incidences of end points
were estimated by the Kaplan-Meier method, and the differ-
ences were assessed by the log-rank test. Hazard ratios
and 95% confidence intervals were estimated with the
Cox proportional hazards model. We used the same Cox
proportional hazards model to estimate P values for interac-
tion in the subgroup analysis. Proportional hazards assump-
tions were assessed on the plots of log(time) vs log
(−log[survival]) and were verified as acceptable. A physician
(H.W.) and a statistician (T.M.) performed all statistical
analyses using JMP version 14.0 and SAS version 9.4 (SAS
Institute Inc). All reported P values were 2-sided and P<.05
was regarded as statistically significant, except for noninfe-
riority testing, in which a 1-sided P<.025 was considered sta-
tistically significant.
Results
Patient Recruitment and Randomization
From December 25, 2015, to December 8, 2017, among 6504
patients eligible for the study, 3045 patients were random-
ized at 90 centers in Japan; 3459 eligible patients were not en-
rolled in the study, mainly because of judgment of attending
physician or patient refusal. Excluding 36 patients who with-
drew consent, 3009 patients were included in the main analy-
sis: 1500 patients in the 1-month DAPT group and 1509 pa-
tients in the 12-month DAPT group (Figure 1). Randomization
wasperformedamedianof1day(interquartilerange,0-4days)
after the index PCI.
Among patients who were eligible for the study, base-
line characteristics were significantly different in several
respects between patients who were or were not enrolled in
the trial. The 3287 nonenrolled patients with baseline infor-
mation were older (mean, 70.0 [SD, 11.7] vs 68.6 [SD, 10.7]
years; P < .001) and had more ST-segment elevation MI
(21.7% vs 18.6%; P = .003), more prior MI (22.7% vs 13.5%;
P < .001), more prior ischemic or hemorrhagic stroke (7.7% vs
6.2%; P = .018), more prior PCI (38.1% vs 34.3%; P = .002),
higher serum creatinine (mean, 1.27 [SD, 1.69] mg/dL vs 1.12
[SD, 1.36 mg/dL]; P < .001), more dialysis (5.2% vs 3.4%;
P < .001), a greater number of target vessels (mean, 1.2 [SD,
0.5] vs 1.1 [SD, 0.4]; P < .001), and more often a left main
coronary artery target (4.7% vs 2.7%; P < .001) than the
enrolled patients (eTable 1 in Supplement 1).
Baseline Characteristics and Medications
The study population reflected a typical Japanese PCI popu-
lation, including patients with advanced age (mean, 68.6
years), male sex (78%), diabetes (39%), stable coronary
artery disease (62%), and acute coronary syndrome (38%).
The majority of patients had low or intermediate thrombotic
and bleeding risks based on both the CREDO-Kyoto risk
score (92% and 93%, respectively) and the PARIS risk score
(86% and 80%, respectively).28,29
Angiographic and proce-
dural characteristics also reflected typical Japanese PCI
practice, with predominance of the radial approach and
intracoronary imaging guidance. The median SYNTAX score
was 9 (categorized as low for coronary anatomic complex-
ity) among 589 patients randomly selected for core labora-
tory assessment. Regarding medications at discharge, stat-
ins were prescribed in 88% of patients and β-blockers in
44%. Proton pump inhibitors were prescribed in 79% of

patients. Baseline characteristics and medications were well
balanced between the 2 groups (Table 1; eTables 2 and 3 in
Supplement 1). Data were missing for prior first-generation
drug-eluting stents in 2 patients, for prior MI in 1 patient, for
anemia in 6 patients, for severe chronic kidney disease in 10
patients, for thrombocytopenia in 11 patients, and for left
ventricular ejection fraction in 246 patients.
Antiplatelet Therapy
For DAPT treatment during month 1, the selected P2Y12
receptor blocker was clopidogrel in 62% of patients and pra-
sugrel in 38% of patients. In the 1-month DAPT group, DAPT
was stopped in 150 patients (10.0%) during the first 30 days,
in 752 patients (50.1%) during the first 37 days, in 1090
patients (72.7%) during the first 44 days, in 1286 patients
(85.7%) during the first 51 days, and in 1428 patients (95.2%)
during the first 60 days, while in the 12-month DAPT group,
DAPT was maintained in 1331 patients (88.2%) for 335 days
and in 848 patients (56.2%) for 365 days (eFigure 1 in
Supplement 1).
1-Year Clinical Outcomes
Final 1-year clinical follow-up was completed in January
2019. Complete 1-year clinical follow-up was achieved in
2974 patients (98.8%) (Figure 1). The primary end point
occurred in 35 patients (2.36%) in the 1-month DAPT
group and in 55 patients (3.70%) in the 12-month DAPT
group. One month of DAPT met criteria for noninferiority
Figure 1. Participant Flow in the STOPDAPT-2 Randomized Clinical Trial
10001 Patients with CoCr-EES implantation
screened for eligibility
6504 Patients eligible for inclusion
3497 Excludeda
1352 Had planned staged percutaneous
coronary intervention
1262 Received drug-eluting stent other
than CoCr-EES
1058 Met exclusion criteria
8 Already enrolled (duplicate)
3459 Excluded
1731 Attending physician judgment
1280 Refused participation
362 Logistic reasons
47 Ethical reasons
39 Unknown reasons
160 Participating in other studies
91 Concomitant disease
83 Difficulty reaching participating
centers
19 Discharged from hospital
34 Difficulty with decision-making
(eg, dementia)
6 Known poor adherence to medication
4 Social factors (eg, poverty)
3 Poor prognosis or end-stage disease
7 Invited to participate after study
enrollment concluded
2 Allergy to aspirin
3045 Randomized
1500 Included in intention-to-
treat analysis
23 Excluded (withdrew consent)
1523 Randomized to 1-month dual
antiplatelet therapy
1521 Received 1-month dual
antiplatelet therapy as
randomized
2 Did not receive intervention
(had received oral
anticoagulation)
1522 Randomized to 12-month
dual antiplatelet therapy
1522 Received 12-month dual
antiplatelet therapy as
randomized
1509 Included in intention-to-
treat analysis
13 Excluded (withdrew consent)
1478 Completed 1-year follow-up
22 Lost to follow-up
23 Withdrew consent
1496 Completed 1-year follow-up
13 Lost to follow-up
13 Withdrew consent
CoCr-EES indicates cobalt-chromium
everolimus-eluting stent.
a
A total of 183 patients had planned
staged procedure and received
other drug-eluting stents, so
numbers are not mutually exclusive.

Table 1. Patient, Lesion, and Procedural Characteristics and Medications
Characteristics 1-Month DAPT (n = 1500) 12-Month DAPT (n = 1509)
Age, mean (SD), y 68.1 (10.9) 69.1 (10.4)
≥75, No. (%) 448 (29.9) 499 (33.1)
Men, No. (%) 1183 (78.9) 1154 (76.5)
Women, No. (%) 317 (21.1) 355 (23.5)
BMI, mean (SD) 24.4 (3.5) 24.2 (3.5)
<25, No. (%) 879 (58.6) 936 (62.0)
Acute coronary syndrome, No. (%)a
565 (37.7) 583 (38.6)
ST-segment elevation myocardial infarction 291 (19.4) 270 (17.9)
Non–ST-segment elevation myocardial infarction 81 (5.4) 99 (6.6)
Unstable anginab
193 (12.9) 214 (14.2)
Stable coronary artery disease, No. (%) 935 (62.3) 926 (61.4)
Prior percutaneous coronary intervention,
No. (%)
503 (33.5) 529 (35.1)
Prior first-generation drug-eluting stents,
No. (%)
65 (4.3) 47 (3.1)
Prior coronary artery bypass graft surgery,
No. (%)
17 (1.1) 42 (2.8)
Prior myocardial infarction, No. (%) 207 (13.8) 199 (13.2)
Prior ischemic or hemorrhagic stroke, No. (%) 81 (5.4) 105 (7.0)
Comorbidities, No. (%)
Hypertension 1105 (73.7) 1116 (74.0)
Hyperlipidemia 1116 (74.4) 1128 (74.8)
Diabetes 585 (39.0) 574 (38.0)
Requiring insulin 104 (6.9) 98 (6.5)
Current smoker 399 (26.6) 311 (20.6)
Anemiac
121 (8.1) 142 (9.4)
Heart failure 115 (7.7) 107 (7.1)
Cancer 114 (7.6) 142 (9.4)
Peripheral artery disease 96 (6.4) 100 (6.6)
Severe chronic kidney diseased
82 (5.5) 84 (5.6)
Estimated glomerular filtration rate
<30 mL/min/1.73 m2
without dialysis
30 (2.0) 34 (2.3)
Dialysis 52 (3.5) 50 (3.3)
Chronic obstructive pulmonary disease 40 (2.7) 44 (2.9)
Atrial fibrillation 35 (2.3) 22 (1.5)
Prior bleeding events 19 (1.3) 28 (1.9)
Thrombocytopeniae
15 (1.0) 16 (1.1)
Cirrhosis 6 (0.4) 4 (0.3)
Left ventricular ejection fraction,
mean (SD), %
59.8 (10.2) 59.7 (10.6)
<40, No. (%) 59/1368 (4.3) 56/1395 (4.0)
PARIS thrombotic risk score, median (IQR)f
3 (1-4) 2 (2-4)
High (≥5), No. (%) 211 (14.1) 215 (14.3)
Intermediate (3-4), No. (%) 560 (37.3) 536 (35.5)
Low (0-2), No. (%) 729 (48.6) 758 (50.2)
PARIS bleeding risk score, median (IQR)f
5 (3-7) 5 (3-7)
High (≥8), No. (%) 302 (20.1) 291 (19.3)
Intermediate (4-7), No. (%) 757 (50.5) 801 (53.1)
Low (0-3), No. (%) 441 (29.4) 417 (27.6)
CREDO-Kyoto thrombotic risk score,
median (IQR)g
1 (0-2) 1 (0-2)
High (≥4), No. (%) 113 (7.5) 122 (8.1)
Intermediate (2-3), No. (%) 318 (21.2) 358 (23.7)
Low (0-1), No. (%) 1069 (71.3) 1029 (68.2)
(continued)

Table 1. Patient, Lesion, and Procedural Characteristics and Medications (continued)
Characteristics 1-Month DAPT (n = 1500) 12-Month DAPT (n = 1509)
CREDO-Kyoto bleeding risk score,
median (IQR)g
0 (0-1) 0 (0-1)
High (≥3), No. (%) 106 (7.1) 112 (7.4)
Intermediate (1-2), No. (%) 398 (26.5) 401 (26.6)
Low (0), No. (%) 996 (66.4) 996 (66.0)
Procedural characteristics
Radial approach, No. (%) 1232 (82.1) 1264 (83.8)
Femoral approach, No. (%) 202 (13.5) 180 (11.9)
Invasive fractional flow reserve, No. (%)h
213 (14.2) 202 (13.4)
No. of target lesions, mean (SD) 1.1 (0.4) 1.1 (0.4)
Target lesion location, No. (%)
Left main coronary artery 43 (2.9) 37 (2.5)
Left anterior descending artery 828 (55.2) 854 (56.6)
Left circumflex coronary artery 268 (17.9) 305 (20.2)
Right coronary artery 436 (29.1) 410 (27.2)
Bypass graft 3 (0.2) 3 (0.2)
Chronic total occlusion, No. (%) 55 (3.7) 67 (4.4)
Bifurcation lesion, No. (%) 376 (25.1) 393 (26.0)
≥2 Target vessels, No. (%) 100 (6.7) 116 (7.7)
Use of intravascular ultrasound, No. (%) 1276 (85.1) 1280 (84.8)
Use of optical coherence tomography, No. (%) 210 (14.0) 233 (15.4)
No. of implanted stents, mean (SD) 1.3 (0.5) 1.3 (0.6)
Minimal stent diameter, mean (SD), mm 2.98 (0.49) 2.96 (0.48)
<3.0, No. (%) 610 (40.7) 627 (41.6)
Total stent length, mean (SD), mm 30.3 (16.7) 30.5 (16.8)
≥28, No. (%) 742 (49.5) 787 (52.2)
Medications at discharge, No. (%)
Aspirin 1497 (99.8) 1509 (100)
P2Y12 receptor blockers 1499 (99.9) 1508 (99.9)
Clopidogrel 903 (60.2) 949 (62.9)
Prasugrel 594 (39.6) 557 (37.0)
Anticoagulants 7 (0.5) 6 (0.4)
Angiotensin converting enzyme inhibitors/
angiotensin II receptor blockers
934 (62.3) 939 (62.2)
β-blockers 672 (44.8) 643 (42.6)
Statins 1318 (87.9) 1318 (87.3)
Proton pump inhibitors 1190 (79.3) 1193 (79.1)
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared);
CREDO-Kyoto, Coronary Revascularization Demonstrating Outcome Study in Kyoto; DAPT, dual antiplatelet therapy;
IQR, interquartile range; PARIS, Patterns of Non-Adherence to Anti-Platelet Regimen in Stented Patients.
a
Acute coronary syndrome was defined as myocardial infarction within 7 days or unstable angina.
b
Unstable angina was defined as Braunwald classification I to III, without confirmation of any biomarker elevation.
c
Anemia was defined as a preprocedural hemoglobin level less than 11 g/dL in both men and women.
d
Severe chronic kidney disease was defined as a preprocedural estimated glomerular filtration rate less than 30
mL/min/1.73 m2
or receipt of maintenance dialysis. Preprocedural creatinine data were missing for 10 patients. Two of
these patients who were undergoing dialysis were included in severe chronic kidney disease, while the other 8 patients
were regarded as not having severe chronic kidney disease.
e
Thrombocytopenia was defined as a preprocedural platelet count less than 100×109
/L.
f
The PARIS thrombotic risk score ranges from 0 to 12 and is categorized as low (0-2), intermediate (3-4), and high (Ն5)
thrombotic risk. The PARIS bleeding risk score ranges from 0 to 15 and is categorized as low (0-3), intermediate (4-7),
and high (Ն8) bleeding risk.
g
The CREDO-Kyoto thrombotic risk score ranges from 0 to 12 and is categorized as low (0-1), intermediate (2-3), and high
(Ն4) thrombotic risk. The CREDO-Kyoto bleeding risk score ranges from 0 to 11 and is categorized as low (0),
intermediate (1 or 2), and high (Ն3) bleeding risk.
h
Invasive fractional flow reserve by intracoronary flow wire, not by computed tomography.

and also met criteria for superiority to 12 months of DAPT
for the primary end point (absolute difference, −1.34% [95%
CI, −2.57% to −0.11%]; HR, 0.64 [95% CI, 0.42-0.98]; P < .001
for noninferiority; P = .04 for superiority) (Figure 2A and
Table 2). From the post hoc analysis model with site as a ran-
dom effect, the effects of multiple sites were nonsignificant
Figure 2. One-Year Time to Events for the Primary and Major Secondary End Points
10
8
6
4
2
0
CumulativeIncidence,%
Days After Index PCI
No. at risk
12-Month DAPT
12-Month DAPT
1-Month DAPT
1-Month DAPT
12-Month DAPT
1-Month DAPT
12-Month DAPT
1-Month DAPT
Primary end point (composite of cardiovascular death, MI, definite stent
thrombosis, ischemic and hemorrhagic stroke, or TIMI major or minor bleeding)
A
0
1509
1500
30
1501
1494
60
1486
1479
90 120
1481
1475
150 180
1469
1468
210 240
1458
1453
270 300
1442
1441
330 360
1159
1151
10
8
6
4
2
0
No. at risk
12-month DAPT
1-month DAPT
Composite of cardiovascular death, MI, definite stent thrombosis,
or ischemic and hemorrhagic stroke
B
0
1509
1500
30
1504
1495
60
1490
1480
90 120
1488
1476
150 180
1479
1471
210 240
1473
1458
270 300
1458
1446
330 360
1172
1157
10
8
6
4
2
0
No. at risk
12-month DAPT
1-month DAPT
TIMI major/minor bleedingC
0
1509
1500
30
1504
1495
60
1491
1483
90 120
1487
1481
150 180
1480
1477
210 240
1471
1467
270 300
1462
1457
330 360
1180
1166
HR, 0.64; 95% CI, 0.42-0.98;
P <.001 for noninferiority;
P =.04 for superiority
HR, 0.79; 95% CI, 0.49-1.29;
P =.005 for noninferiority;
HR, 0.26; 95% CI, 0.11-0.64;
Log-rank P =.04
Log-rank P =.34
Log-rank P =.002 HR indicates hazard ratio;
MI, myocardial infarction; PCI,
percutaneous coronary intervention;
TIMI, Thrombolysis in Myocardial
Infarction. The median observation
periods in the last data set were 400
(interquartile range, 368-732) days in
the 1-month dual antiplatelet therapy
(DAPT) group and 414 (interquartile
range, 369-733) days in the 12-month
DAPT group. The last day of data
collection was day 365; patients with
follow-up beyond 1 year were
censored on day 366.

Table 2. Clinical Outcomes at 1 Year
Outcomes
No. of Patients With Event (Cumulative Incidence, %)a
Hazard Ratio (95% CI)
P Valueb
1-Month DAPT (n = 1500) 12-Month DAPT (n = 1509) Noninferiority Superiority
Primary End Point
Composite of cardiovascular death, myocardial
infarction, definite stent thrombosis,
ischemic or hemorrhagic stroke,
or TIMI major or minor bleeding
35 (2.36) 55 (3.70) 0.64 (0.42-0.98) <.001 .04
Major Secondary End Points
Cardiovascular end point: composite
of cardiovascular death, myocardial
infarction, definite stent thrombosis,
or ischemic or hemorrhagic stroke
29 (1.96) 37 (2.51) 0.79 (0.49-1.29) .005 .34
Bleeding end point: TIMI major
or minor bleeding
6 (0.41) 23 (1.54) 0.26 (0.11-0.64) .004
Other Secondary End Points
Death 21 (1.42) 18 (1.21) 1.18 (0.63-2.21) .61
Death due to cardiac cause (post hoc) 8 (0.54) 8 (0.54) 1.01 (0.38-2.69) .98
Death due to cardiovascular cause 9 (0.61) 11 (0.74) 0.83 (0.34-1.99) .67
Death due to noncardiovascular cause
(post hoc)
12 (0.82) 7 (0.47) 1.73 (0.68-4.40) .25
Myocardial infarction 13 (0.88) 11 (0.75) 1.19 (0.54-2.67) .66
Large myocardial infarction
(CK-MB ≥10 × ULN) (post hoc)
5 (0.34) 2 (0.13) 2.52 (0.49-13.01) .27
Small myocardial infarction
(CK-MB <10 × ULN) (post hoc)
7 (0.48) 5 (0.34) 1.42 (0.45-4.46) .55
Myocardial infarction without
CK-MB elevation (post hoc)
1 (0.07) 2 (0.14) 0.51 (0.05-5.59) .58
Myocardial infarction without
measurement of CK-MB (post hoc)
0 2 (0.13)
Definite stent thrombosis 2 (0.13) 1 (0.07) 2.02 (0.18-22.26) .57
Definite or probable stent thrombosis 4 (0.27) 1 (0.07) 4.03 (0.45-36.08) .21
Stroke (ischemic or hemorrhagic) 8 (0.54) 16 (1.09) 0.50 (0.22-1.18) .11
Ischemic (post hoc) 8 (0.54) 15 (1.03) 0.54 (0.23-1.27) .16
Hemorrhagic (post hoc) 0 1 (0.07)
Bleedingc
TIMI major 3 (0.20) 16 (1.07) 0.19 (0.05-0.65) .01
TIMI minor 3 (0.20) 7 (0.47) 0.43 (0.11-1.67) .22
BARC type 3 or 5 8 (0.54) 27 (1.81) 0.30 (0.13-0.65) .003
BARC type 5 1 (0.07) 3 (0.20) 0.34 (0.03-3.23) .34
BARC type 3 7 (0.47) 24 (1.61) 0.29 (0.13-0.68) .004
GUSTO moderate or severe 6 (0.40) 23 (1.54) 0.26 (0.11-0.64) .004
GUSTO severe 4 (0.27) 11 (0.74) 0.37 (0.12-1.15) .09
GUSTO moderate 2 (0.14) 12 (0.80) 0.17 (0.04-0.75) .02
Intracranial (post hoc) 2 (0.14) 5 (0.34) 0.40 (0.08-2.08) .29
Gastrointestinal 6 (0.40) 19 (1.27) 0.32 (0.13-0.79) .01
Death or myocardial infarction 32 (2.17) 29 (1.95) 1.11 (0.67-1.84) .67
Cardiovascular death or myocardial infarction 21 (1.42) 22 (1.48) 0.96 (0.53-1.75) .90
Major adverse cardiac eventsd
38 (2.57) 32 (2.19) 1.20 (0.75-1.93) .44
Any coronary revascularizatione
98 (6.77) 76 (5.26) 1.31 (0.97-1.77) .08
TLR 35 (2.38) 23 (1.60) 1.55 (0.91-2.62) .10
Clinically driven 26 (1.77) 19 (1.32) 1.39 (0.77-2.51) .28
Non-TLR 71 (4.93) 60 (4.13) 1.20 (0.85-1.69) .30
Coronary artery bypass graft surgery 6 (0.42) 5 (0.34) 1.21 (0.37-3.98) .75
Abbreviations: BARC, Bleeding Academic Research Consortium; CK-MB, creatine
kinase MB; DAPT, dual antiplatelet therapy; GUSTO, Global Use of Strategies
to Open Occluded Arteries; PCI, percutaneous coronary intervention;
TIMI, Thrombolysis in Myocardial Infarction; TLR, target lesion revascularization;
ULN, upper limit of normal.
a
Percentages are Kaplan-Meier estimates at day 365.
b
P values are derived from Cox proportional hazards model.
c
For details of the TIMI, BARC, and GUSTO bleeding criteria, see eAppendix 3 in
Supplement 1.
d
Major adverse cardiac events are defined as a composite of cardiac death,
myocardial infarction, and clinically TLR.
e
Clinical events after randomization.

(eTable 4 in Supplement 1). Noninferiority of 1 month of
DAPT compared with 12 months of DAPT was also confirmed
for the primary end point in the per-protocol population
(absolute difference, −0.62% [95% CI, −1.77% to 0.53%]; HR,
0.77 [95% CI, 0.47-1.26]; P = .004 for noninferiority) and in
the as-treated population (absolute difference −0.30% [95%
CI, −1.45% to .85%]; HR, 0.89 [95% CI, 0.56-1.42]; P = .015 for
noninferiority) as well as in the sensitivity analysis (absolute
difference, −0.02% [95% CI, −1.38% to 1.34%]; HR, 1.00 [95%
CI, 0.69-1.46]; P = .02 for noninferiority) (eTable 5 and eFig-
ures 2-4 in Supplement 1).
For the major secondary cardiovascular end point, 1
month of DAPT also met criteria for noninferiority to 12
months of DAPT (1.96% vs 2.51%; absolute difference,
−0.55% [95% CI, −1.62% to 0.52%]; HR, 0.79 [95% CI, 0.49-
1.29]; P = .005 for noninferiority; P = .34 for superiority). For
the major secondary bleeding end point, 1 month of DAPT
was superior to 12 months of DAPT (0.41% vs 1.54%; abso-
lute difference, −1.13% [95% CI, −1.84% to −0.42%]; HR,
0.26 [95% CI, 0.11-0.64]; P = .004) (Figure 2, B and C, and
Table 2). The incidence of bleeding was consistently lower in
the 1-month DAPT group than in the 12-month DAPT group
by BARC type 3 or 5 criteria (0.54% vs 1.81%; absolute differ-
ence, −1.27% [95% CI, −2.03% to −0.51%]; HR, 0.30 [95% CI,
0.13-0.65]; P = .003) and by GUSTO moderate or severe crite-
ria (0.40% vs 1.54%; absolute difference, −1.14% [95% CI,
−1.84% to −0.44%]; HR, 0.26 [95% CI, 0.11-0.64]; P = .004)
(Table 2). Five additional secondary bleeding end points
were statistically significantly more frequent in the
12-month DAPT group than in the 1-month DAPT group
(Table 2). The incidence of definite or probable stent throm-
bosis was very low: 4 patients (0.27%) in the 1-month DAPT
group and 1 patient (0.07%) in the 12-month DAPT group.
Two probable stent thrombosis events in the 1-month DAPT
group occurred within 1 month before stopping aspirin
(eTable 6 in Supplement 1).
The results from the 30-day and 60-day landmark
analyses were consistent with the main analyses for the pri-
mary end point (30 days: 2.04% vs 3.25%; absolute differ-
ence, −1.21% [95% CI, −2.37% to −0.05%]; HR, 0.63 [95% CI,
0.40-0.99]; P < .001 for noninferiority; P = .045 for superi-
ority; 60 days: 1.84% vs 2.99%; absolute difference, −1.15%
[95% CI, −2.25% to −0.05%]; HR, 0.62 [95% CI, 0.38-0.99];
P < .001 for noninferiority; P = .047 for superiority)
(eTables 7 and 8 in Supplement 1).
Subgroup Analysis
In the subgroup analysis, the lower risk of 1 month of DAPT
compared with 12 months of DAPT for the primary end point
was consistently seen across subgroups except for the small
subgroup of patients with severe chronic kidney disease
(P = .03 for interaction). Patients with high PARIS and
CREDO-Kyoto thrombotic risk scores had numerically higher
incidences of the primary end point than patients with inter-
mediate or low scores (PARIS: high, 8.90%; intermediate,
3.42%; and low, 2.40% in the 12-month DAPT group and
high, 4.39%; intermediate, 3.07%; and low, 1.24% in the
1-month DAPT group; CREDO-Kyoto: high, 7.41%; intermedi-
ate, 5.94%; and low, 2.47% in the 12-month DAPT group and
high, 7.24%; intermediate, 2.25%; and low, 1.89% in the
1-month DAPT group). However, there was no significant
interaction between the subgroup factors of PARIS and
CREDO-Kyoto thrombotic risk scores and the effects of 1
month of DAPT compared with 12 months of DAPT on the
primary end point (P = .39 [PARIS] and P = .27 [CREDO-
Kyoto] for interaction) (Figure 3).
Discussion
In this randomized clinical trial, 1 month of DAPT followed
by clopidogrel monotherapy met criteria for noninferiority
and also was associated with a net clinical benefit for the
primary end point, a composite of cardiovascular and
bleeding events, compared with 12 months of DAPT with
aspirin and clopidogrel after CoCr-EES implantation.
In addition, 1 month of DAPT was noninferior for the cardio-
vascular composite secondary end point and superior for
the major secondary bleeding end point compared with 12
months of DAPT.
In previous studies, attempts to deescalate the intensity
of DAPT were initiated mainly in patients at high bleed-
ing risk. The LEADERS FREE trial compared drug-coated
stents with bare-metal stents under the protocol of 1 month
of DAPT in patients at high bleeding risk.30
Despite a very
short duration of DAPT, the 1-year incidence of major
bleeding (BARC type 3, 4, or 5) was as high as 7%. Therefore,
the standard DAPT regimen would not be appropriate,
and further de-escalation of antiplatelet therapy might be
preferable in these patients at high risk of bleeding. The
GLOBAL LEADERS trial explored an experimental regimen
of 1 month of DAPT followed by ticagrelor monotherapy
for up to 24 months compared with the standard 12 months
of DAPT followed by aspirin monotherapy for up to 24
months regardless of patients’ bleeding risk. The post hoc
analysis within 12 months demonstrated significant reduc-
tion of the primary end point of all-cause death and new
Q-wave MI in the experimental group, suggesting a possible
benefit of stopping aspirin at 1 month followed by ticagrelor
monotherapy, although the overall trial result was negative
at 2 years.31
The present study also explored 1 month of DAPT after
CoCr-EES implantation. One month of DAPT followed
by clopidogrel monotherapy provided a net clinical benefit
for a composite of cardiovascular and bleeding events com-
pared with 12 months of DAPT with aspirin and clopidogrel.
The benefit was driven by a significant reduction of bleed-
ing events without an increase in cardiovascular events.
Therefore, the very short DAPT duration of 1 month would
be a potential option even in patients without high bleeding
risk. Given the very low rates of stent thrombosis in studies
using contemporary drug-eluting stents, avoiding bleeding
with de-escalation of antiplatelet therapy may be more
important than attempting further reduction of stent
thrombosis with intensive antiplatelet therapy.12,15,16
There
may be some patients with very high ischemic risk, who

might benefit from more intensive antithrombotic therapy.
Nevertheless, in the subgroup analysis of the present study,
there was no interaction between thrombotic risk scores
and the effect of 1 month of DAPT compared with 12 months
of DAPT for the primary end point. Furthermore, in general,
patients with very high ischemic risk also have high bleed-
ing risk, making the choice of intensive antithrombotic
therapy difficult.28
Further studies would be needed to rec-
oncile the concept of very short mandatory DAPT duration
with the demonstrated ischemic benefit with more inten-
sive antithrombotic regimens such as DAPT using ticagrelor
or low-dose rivaroxaban with aspirin in patients with very
high ischemic risk.32,33
This study suggested that 1 month of
DAPT may be sufficient after PCI using CoCr-EES in a popu-
lation at low ischemic risk such as was enrolled in the
present study. Very short DAPT in a population at high
bleeding risk may be a viable option but needs further study
because of the high ischemic risk of this population.
Figure 3. Subgroup Analyses for the Effect of 1-Month DAPT on the Primary End Point
P Value P Value for
Interaction
0.1 8
Favors
1-Month DAPT
Favors
12-Month DAPT
1
HR (95% CI)
No./Total (%)
1-Month DAPT
(n=1500)
12-Month DAPT
(n=1509)
Age, y
HR
(95% CI)
10/448 (2.26) 25/499 (5.08)≥75 0.44 (0.21-0.92) .03
25/1052 (2.41) 30/1010 (3.02)<75 0.80 (0.47-1.36) .41
Acute coronary syndrome
16/565 (2.88) 23/583 (4.02)Yes 0.72 (0.38-1.36) .44
19/935 (2.05) 32/926 (3.49)No 0.59 (0.33-1.03) .06
STEMI
9/291 (3.15) 14/270 (5.26)Yes 0.60 (0.26-1.38) .23
26/1209 (2.18) 41/1239 (3.36)No 0.65 (0.40-1.06) .08
Severe chronic kidney disease
9/82 (11.22) 5/84 (5.97)Yes 1.93 (0.65-5.75) .24
26/1418 (1.86) 50/1425 (3.56)No 0.52 (0.32-0.84) .007
Diabetes
18/585 (3.12) 25/574 (4.45)Yes 0.70 (0.38-1.29) .26
17/915 (1.88) 30/935 (3.24)No 0.58 (0.32-1.05) .07
Total stent length ≥28 mm
19/742 (2.60) 33/787 (4.23)Yes 0.61 (0.35-1.07) .08
16/758 (2.14) 22/722 (3.12)No 0.69 (0.36-1.32) .26
≥2 Target vessels
4/100 (4.14) 8/116 (6.94)Yes 0.58 (0.17-1.92) .37
31/1400 (2.24) 47/1393 (3.43)No 0.66 (0.42-1.03) .07
9/729 (1.24) 18/758 (2.40)Low 0.52 (0.23-1.15) .11
PARIS thrombotic risk score
9/211 (4.39) 19/215 (8.90)High 0.47 (0.21-1.05) .06
17/560 (3.07) 18/536 (3.42)Intermediate 0.91 (0.47-1.77) .78
5/441 (1.15) 7/417 (1.72)Low 0.68 (0.21-2.13) .50
PARIS bleeding risk score
13/302 (4.37) 25/291 (8.62)High 0.49 (0.25-0.96) .04
17/757 (2.27) 23/801 (2.93)Intermediate 0.78 (0.42-1.46) .44
20/1069 (1.89) 25/1029 (2.47)Low 0.77 (0.43-1.39) .38
CREDO-Kyoto thrombotic risk score
8/113 (7.24) 9/122 (7.41)High 0.97 (0.37-2.51) .95
7/318 (2.25) 21/358 (5.94)Intermediate 0.37 (0.16-0.87) .02
14/996 (1.42) 27/996 (2.75)Low 0.52 (0.27-0.99) .045
35/1500 (2.36) 55/1509 (3.70)Overall 0.64 (0.42-0.98) .04
CREDO-Kyoto bleeding risk score
7/106 (6.70) 10/112 (8.93)High 0.73 (0.28-1.91) .52
14/398 (3.58) 18/401 (4.57)Intermediate 0.79 (0.39-1.59) .51
.20
.64
.87
.03
.65
.76
.85
.39
.61
.27
.66
CREDO-Kyoto indicates Coronary Revascularization Demonstrating Outcome
Study in Kyoto; HR, hazard ratio; PARIS, Patterns of Non-Adherence to
Anti-Platelet Regimen in Stented Patients; STEMI, ST-segment elevation
myocardial infarction. The vertical dashed line indicates the prespecified
relative 50% noninferiority margin. Numbers and percentages shown are
number of patients with event/number of patients at risk and incidences at
1 year. Acute coronary syndrome was the clinical presentation for the index
percutaneous coronary intervention. Severe chronic kidney disease is defined
as preprocedural estimated glomerular filtration rate less than
30 mL/min/1.73 m2
or undergoing maintenance dialysis. See Table 1 for
definitions of PARIS and CREDO-Kyoto risk scores.

Limitations
This study has several limitations. First, a composite end
point assessing both cardiovascular and bleeding events was
used as the primary end point to evaluate the net clinical
benefit. However, a consensus has not been yet reached on
the definition and validity of the end point evaluating net
clinical benefit, although it would be relevant for comparing
a given antithrombotic regimen with another.34
Second, the
present study was not powered for noninferiority for the
major secondary cardiovascular composite end point. Third,
the present study could not assess the risk of stent thrombo-
sis with very short DAPT. Fourth, the lower-than-expected
actual event rate for the primary end point reduced the sta-
tistical power of this noninferiority study. In addition,
patients were randomized not at 1 month but shortly after
PCI. Therefore, the noninferiority analysis included patients
who had an event before 1 month, making the difference
between the 1-month and 12-month DAPT groups smaller.
However, the results from the 30-day landmark analysis
excluding patients who had an event before 1 month were
fully consistent with the main results. Fifth, the majority of
enrolled patients had low or intermediate ischemic risk.
Many eligible patients were not enrolled in the study by the
judgment of the attending physicians, suggesting the possi-
bility of selective enrollment of patients with low ischemic
risk. Indeed, among the patients who were eligible for the
study, the baseline characteristics were different in several
aspects between patients who did vs did not enroll in the
trial. However, the majority of patients in the derivation
cohort of the CREDO-Kyoto risk score, in which patients
with first coronary revascularization were consecutively
enrolled, also had low or intermediate ischemic risk, sug-
gesting that patients with high ischemic risk may not be
dominant in the Japanese PCI population.28
Regarding the
generalizability of the present study results, further research
would be warranted in patients with high ischemic risk.
Sixth, we chose clopidogrel rather than the more commonly
used aspirin as the antiplatelet agent for monotherapy in the
1-month DAPT group. Therefore, we could not assess the
role of aspirin monotherapy shortly after the very short
DAPT period, although the incidence of adverse events with
aspirin monotherapy beyond 3 months was acceptable in the
STOPDAPT study.12
In terms of long-term therapy, clopido-
grel monotherapy will continue to be compared with aspirin
monotherapy beyond 12 months and up to 5 years in the
present study. Seventh, it is well known that Japanese
patients with coronary artery disease have lower ischemic
risk compared with US and European patients.9,35,36
Further-
more, potent P2Y12 receptor blockers such as ticagrelor or
standard-dose prasugrel were not available in Japan. In addi-
tion, the vast majority of patents in this study underwent
PCI guided by intracoronary imaging devices, which are
rarely used in the United States and Europe. Therefore, cau-
tion is warranted in extrapolating the current study results
outside of Japan. Eighth, this study was conducted exclu-
sively in patients who received CoCr-EES, and therefore, it is
unknown whether the present study results may be extrapo-
lated to other currently used drug-eluting stents. Ninth, the
open-label trial design has inherent limitations. However,
the majority of patients followed the assigned antiplatelet
regimen appropriately, and the components of the primary
composite end point in this study were less likely to be
affected by the open-label trial design.
Conclusions
Among patients undergoing PCI using CoCr-EES, 1 month
of DAPT followed by clopidogrel monotherapy, compared
with 12 months of DAPT with aspirin and clopidogrel,
resulted in a significantly lower rate of a composite of car-
diovascular and bleeding events, meeting criteria for both
noninferiority and superiority. These findings suggest that a
shorter duration of DAPT may provide benefit, although
given the study limitations, additional research is needed in
other populations.
ARTICLE INFORMATION
Accepted for Publication: May 23, 2019.
Author Affiliations: Department of Cardiovascular
Medicine, Kyoto University Graduate School of
Medicine, Kyoto, Japan (Watanabe, Shiomi,
Kimura); Department of Cardiology, Kokura
Memorial Hospital, Kitakyusyu, Japan (Domei,
Ando); Department of Clinical Epidemiology, Hyogo
College of Medicine, Nishinomiya, Japan
(Morimoto); Department of Cardiovascular
Medicine, Saga University, Saga, Japan (Natsuaki);
Department of Cardiovascular Medicine, Kobe City
Medical Center General Hospital, Kobe, Japan
(Toyota, Furukawa); Department of Cardiology,
Kurashiki Central Hospital, Kurashiki, Japan (Ohya,
Kadota); Department of Cardiology, Juntendo
University Shizuoka Hospital, Izunokuni, Japan
(Suwa); Department of Cardiology, Ogaki Municipal
Hospital, Ogaki, Japan (Takagi); Department of
Cardiology, Japanese Red Cross Nagoya Daini
Hospital, Nagoya, Japan (Nanasato); Department of
Cardiology, Minamino Cardiovascular Hospital,
Hachioji, Japan (Hata); Department of Cardiology,
Sendai Cardiovascular Center, Sendai, Japan (Yagi);
Department of Cardiology, Saiseikai Fukuoka
General Hospital, Fukuoka, Japan (Suematsu);
Department of Cardiology, Mitsubishi Kyoto
Hospital, Kyoto, Japan (Yokomatsu); Department of
Cardiology, Sakakibara Heart Institute, Fuchu,
Japan (Takamisawa); Department of Cardiology,
Kagawa Prefectural Central Hospital, Takamatsu,
Japan (Doi); Department of Cardiology, Gifu
Prefectural General Medical Center, Gifu, Japan
(Noda); Department of Cardiology, Ehime
Prefectural Central Hospital, Matsuyama, Japan
(Okayama); Department of Cardiology, Hoshi
General Hospital, Koriyama, Japan (Seino);
Department of Cardiology, Shizuoka General
Hospital, Shizuoka, Japan (Tada, Sakamoto);
Division of Cardiology, Yokohama City University
Medical Center, Yokohama, Japan (Hibi);
Department of Cardiology, National Hospital
Organization Kyoto Medical Center, Kyoto, Japan
(Abe); Department of Cardiology, Chikamori
Hospital, Kochi, Japan (Kawai); Division of
Cardiology, Saiseikai Kumamoto Hospital
Cardiovascular Center, Kumamoto, Japan (Nakao);
Department of Cardiology, Mitsui Memorial
Hospital, Tokyo, Japan (Tanabe); Department of
Cardiology, Tokai University Hospital, Isehara,
Japan (Ikari); Hanaoka Seishu Memorial
Cardiovascular Clinic, Sapporo, Japan (Hanaoka);
Department of Cardiology, Iwate Medical University
Hospital, Morioka, Japan (Morino); Department of
Cardiology, Teikyo University Hospital, Tokyo,
Japan (Kozuma); Department of Cardiovascular
Medicine, Shiga University of Medical Science,
Otsu, Japan (Nakagawa).
Author Contributions: Dr Kimura had full access to
all of the data in the study and takes responsibility
for the integrity of the data and the accuracy of the
data analysis.
Concept and design: Domei, Morimoto, Natsuaki,
Toyota, Ohya, Takagi, Suematsu, Yokomatsu,
Takamisawa, Abe, Kawai, Nakao, Tanabe, Morino,
Kozuma, Nakagawa, Kimura.
Acquisition, analysis, or interpretation of data:
Watanabe, Domei, Morimoto, Natsuaki, Shiomi,

Toyota, Ohya, Suwa, Nanasato, Hata, Yagi,
Takamisawa, Doi, Noda, Okayama, Seino,
Tada, Sakamoto, Hibi, Nakao, Ando, Tanabe,
Ikari, Hanaoka, Morino, Kozuma, Kadota,
Furukawa, Kimura.
Drafting of the manuscript: Watanabe, Domei,
Toyota, Hata, Suematsu, Yokomatsu, Kawai,
Hanaoka, Kadota, Kimura.
Critical revision of the manuscript for important
intellectual content: Watanabe, Domei, Morimoto,
Natsuaki, Shiomi, Toyota, Ohya, Suwa, Takagi,
Nanasato, Yagi, Takamisawa, Doi, Noda, Okayama,
Seino, Tada, Sakamoto, Hibi, Abe, Nakao, Ando,
Tanabe, Ikari, Morino, Kozuma, Furukawa,
Nakagawa, Kimura.
Statistical analysis: Watanabe, Morimoto, Shiomi,
Toyota.
Obtained funding: Takagi, Kimura.
Administrative, technical, or material support:
Watanabe, Morimoto, Natsuaki, Suwa, Nanasato,
Doi, Noda, Okayama, Abe, Nakao, Tanabe,
Hanaoka, Furukawa, Nakagawa, Kimura.
Supervision: Morimoto, Ohya, Sakamoto, Kawai,
Ando, Tanabe, Ikari, Morino, Nakagawa, Kimura.
Conflict of Interest Disclosures: Dr Watanabe
reported receipt of personal fees from Abbott
Vascular Japan and Daiichi Sankyo. Dr Yagi
reported receipt of personal fees from Otsuka
Pharmaceutical, Daiichi Sankyo, and Kowa
Pharmaceuticals. Dr Hibi reported receipt of
personal fees from Abbott Vascular. Dr Nakao
reported receipt of personal fees from Sanofi,
Bayer, Daiichi-Sankyo, and Boehringer Ingelheim.
Dr Tanabe reported receipt of personal fees from
Abbott Vascular, AstraZeneca, Sanofi, Daiichi
Sankyo, Terumo, Boston Scientific, Japan Lifeline,
Bayer, and Medtronic and advisory board
membership for Abbott Vascular and Terumo
Japan. Dr Morino reported receipt of personal fees
from Abbott Vascular and advisory board
membership for Abbott Vascular and Terumo
Japan. Dr Kozuma reported receipt of grants and
personal fees from Abbott Vascular and advisory
board membership for Abbott Vascular and Terumo
Japan. Dr Furukawa reported receipt of personal
fees from Daiichi Sankyo, Bayer, and Sanofi.
Dr Nakagawa reported advisory board membership
for Abbott Vascular. Dr Kimura reported receipt of
personal fees from Abbott Vascular and grants from
Abbott Vascular and Boston Scientific and advisory
board membership for Abbott Vascular and Terumo
Japan. No other disclosures were reported.
Funding/Support: Abbott Vascular funded the
STOPDAPT-2 study but did not provide medications
or coronary devices.
Role of the Funder/Sponsor: Abbott Vascular was
involved in discussions regarding the study design
but was not involved in the conduct of the study
nor in the collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of the manuscript; or decision to submit
the manuscript for publication. The sponsor did not
have the right to veto publication or to control the
decision regarding to which journal the manuscript
was submitted.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We thank the study
investigators for their efforts in enrolling patients
and collecting data and the members of the
Research Institute for Production Development for
coordinating the study. Yusuke Yoshikawa, MD,
Department of Cardiovascular Medicine, Kyoto
University Graduate School of Medicine,
contributed to additional analyses in manuscript
revision without receipt of compensation.
REFERENCES
1. Levine GN, Bates ER, Bittl JA, et al. 2016
ACC/AHA guideline focused update on duration of
dual antiplatelet therapy in patients with coronary
artery disease: a report of the American College of
Cardiology/American Heart Association Task Force
on Clinical Practice Guidelines: an update of the
2011 ACCF/AHA/SCAI guideline for percutaneous
coronary intervention, 2011 ACCF/AHA guideline for
coronary artery bypass graft surgery, 2012
ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for
the diagnosis and management of patients with
stable ischemic heart disease, 2013 ACCF/AHA
guideline for the management of ST-elevation
myocardial infarction, 2014 AHA/ACC guideline for
the management of patients with non-ST-elevation
acute coronary syndromes, and 2014 ACC/AHA
guideline on perioperative cardiovascular
evaluation and management of patients
undergoing noncardiac surgery. Circulation. 2016;
134(10):e123-e155.
2. Valgimigli M, Bueno H, Byrne RA, et al; ESC
Scientific Document Group; ESC Committee for
Practice Guidelines; ESC National Cardiac Societies.
2017 ESC focused update on dual antiplatelet
therapy in coronary artery disease developed in
collaboration with EACTS: the Task Force for Dual
Antiplatelet Therapy in Coronary Artery Disease of
the European Society of Cardiology (ESC) and of
the European Association for Cardio-Thoracic
Surgery (EACTS). Eur Heart J. 2018;39(3):213-260.
doi:10.1093/eurheartj/ehx419
3. Palmerini T, Benedetto U, Bacchi-Reggiani L,
et al. Mortality in patients treated with extended
duration dual antiplatelet therapy after drug-eluting
stent implantation: a pairwise and Bayesian
network meta-analysis of randomised trials. Lancet.
2015;385(9985):2371-2382. doi:10.1016/S0140-6736
(15)60263-X
4. Toyota T, Shiomi H, Morimoto T, Natsuaki M,
Kimura T. Short versus prolonged dual antiplatelet
therapy (DAPT) duration after coronary stent
implantation: a comparison between the DAPT
study and 9 other trials evaluating DAPT duration.
PLoS One. 2017;12(9):e0174502. doi:10.1371/
journal.pone.0174502
5. Mauri L, Kereiakes DJ, Yeh RW, et al; DAPT Study
Investigators. Twelve or 30 months of dual
antiplatelet therapy after drug-eluting stents.
N Engl J Med. 2014;371(23):2155-2166. doi:10.1056/
NEJMoa1409312
6. Räber L, Magro M, Stefanini GG, et al. Very late
coronary stent thrombosis of a newer-generation
everolimus-eluting stent compared with
early-generation drug-eluting stents: a prospective
cohort study. Circulation. 2012;125(9):1110-1121. doi:
10.1161/CIRCULATIONAHA.111.058560
7. Scandinavian Simvastatin Survival Study Group.
Randomised trial of cholesterol lowering in 4444
patients with coronary heart disease: the
Scandinavian Simvastatin Survival Study (4S). Lancet.
1994;344(8934):1383-1389.
8. Cannon CP, Braunwald E, McCabe CH, et al;
Pravastatin or Atorvastatin Evaluation and Infection
Therapy-Thrombolysis in Myocardial Infarction 22
Investigators. Intensive versus moderate lipid
lowering with statins after acute coronary
syndromes. N Engl J Med. 2004;350(15):1495-1504.
doi:10.1056/NEJMoa040583
9. Taguchi I, Iimuro S, Iwata H, et al. High-dose
versus low-dose pitavastatin in Japanese patients
with stable coronary artery disease (REAL-CAD):
a randomized superiority trial. Circulation. 2018;137
(19):1997-2009. doi:10.1161/CIRCULATIONAHA.117.
032615
10. Généreux P, Giustino G, Witzenbichler B, et al.
Incidence, predictors, and impact of post-discharge
bleeding after percutaneous coronary intervention.
J Am Coll Cardiol. 2015;66(9):1036-1045. doi:10.
1016/j.jacc.2015.06.1323
11. Valgimigli M, Costa F, Lokhnygina Y, et al.
Trade-off of myocardial infarction vs bleeding types
on mortality after acute coronary syndrome:
lessons from the Thrombin Receptor Antagonist for
Clinical Event Reduction in Acute Coronary
Syndrome (TRACER) randomized trial. Eur Heart J.
2017;38(11):804-810.
12. Natsuaki M, Morimoto T, Yamamoto E, et al.
One-year outcome of a prospective trial stopping
dual antiplatelet therapy at 3 months after
everolimus-eluting cobalt-chromium stent
implantation: Short and Optimal Duration of Dual
Antiplatelet Therapy After Everolimus-Eluting
Cobalt-Chromium Stent (STOPDAPT) trial.
Cardiovasc Interv Ther. 2016;31(3):196-209. doi:10.
1007/s12928-015-0366-9
13. World Medical Association. World Medical
Association Declaration of Helsinki: ethical
principles for medical research involving human
subjects. JAMA. 2013;310(20):2191-2194. doi:10.
1001/jama.2013.281053
14. Otsuka F, Cheng Q, Yahagi K, et al. Acute
thrombogenicity of a durable polymer
everolimus-eluting stent relative to contemporary
drug-eluting stents with biodegradable polymer
coatings assessed ex vivo in a swine shunt model.
JACC Cardiovasc Interv. 2015;8(9):1248-1260. doi:
10.1016/j.jcin.2015.03.029
15. Palmerini T, Benedetto U, Biondi-Zoccai G, et al.
Long-term safety of drug-eluting and bare-metal
stents: evidence from a comprehensive network
meta-analysis. J Am Coll Cardiol. 2015;65(23):2496-
2507. doi:10.1016/j.jacc.2015.04.017
16. Kimura T, Morimoto T, Natsuaki M, et al; RESET
Investigators. Comparison of everolimus-eluting
and sirolimus-eluting coronary stents: 1-year
outcomes from the Randomized Evaluation of
Sirolimus-Eluting Versus Everolimus-Eluting Stent
Trial (RESET). Circulation. 2012;126(10):1225-1236.
doi:10.1161/CIRCULATIONAHA.112.104059
17. Sianos G, Morel MA, Kappetein AP, et al. The
SYNTAX score: an angiographic tool grading the
complexity of coronary artery disease.
EuroIntervention. 2005;1(2):219-227.
18. Leon MB, Baim DS, Popma JJ, et al; Stent
Anticoagulation Restenosis Study Investigators.
A clinical trial comparing three antithrombotic-drug
regimens after coronary-artery stenting. N Engl J Med.
1998;339(23):1665-1671. doi:10.1056/
NEJM199812033392303
19. Schömig A, Neumann FJ, Kastrati A, et al.
A randomized comparison of antiplatelet and
anticoagulant therapy after the placement of
coronary-artery stents. N Engl J Med. 1996;334(17):
1084-1089. doi:10.1056/NEJM199604253341702

20. CAPRIE Steering Committee. A randomised,
blinded, trial of clopidogrel versus aspirin in
patients at risk of ischaemic events (CAPRIE). Lancet.
1996;348(9038):1329-1339. doi:10.1016/S0140-6736
(96)09457-3
21. Capodanno D, Mehran R, Valgimigli M, et al.
Aspirin-free strategies in cardiovascular disease
and cardioembolic stroke prevention. Nat Rev Cardiol.
2018;15(8):480-496. doi:10.1038/s41569-
018-0049-1
22. Rao AK, Pratt C, Berke A, et al. Thrombolysis in
Myocardial Infarction (TIMI) trial—phase I:
hemorrhagic manifestations and changes in plasma
fibrinogen and the fibrinolytic system in patients
treated with recombinant tissue plasminogen
activator and streptokinase. J Am Coll Cardiol. 1988;
11(1):1-11. doi:10.1016/0735-1097(88)90158-1
23. Cutlip DE, Windecker S, Mehran R, et al;
Academic Research Consortium. Clinical end points
in coronary stent trials: a case for standardized
definitions. Circulation. 2007;115(17):2344-2351.
24. Mehran R, Rao SV, Bhatt DL, et al. Standardized
bleeding definitions for cardiovascular clinical trials:
a consensus report from the Bleeding Academic
Research Consortium. Circulation. 2011;123(23):
2736-2747. doi:10.1161/CIRCULATIONAHA.110.
009449
25. GUSTO investigators. An international
randomized trial comparing four thrombolytic
strategies for acute myocardial infarction. N Engl J
Med. 1993;329(10):673-682. doi:10.1056/
NEJM199309023291001
26. Serruys PW, Morice MC, Kappetein AP, et al;
SYNTAX Investigators. Percutaneous coronary
intervention versus coronary-artery bypass grafting
for severe coronary artery disease. N Engl J Med.
2009;360(10):961-972. doi:10.1056/
NEJMoa0804626
27. Park SJ, Kim YH, Park DW, et al. Randomized
trial of stents versus bypass surgery for left main
coronary artery disease. N Engl J Med. 2011;364
(18):1718-1727. doi:10.1056/NEJMoa1100452
28. Natsuaki M, Morimoto T, Yamaji K, et al;
CREDO‐Kyoto PCI/CABG Registry Cohort 2, RESET,
and NEXT Trial Investigators. Prediction of
thrombotic and bleeding events after percutaneous
coronary intervention: CREDO-Kyoto thrombotic
and bleeding risk scores. J Am Heart Assoc. 2018;7
(11):e008708. doi:10.1161/JAHA.118.008708
29. Baber U, Mehran R, Giustino G, et al. Coronary
thrombosis and major bleeding after PCI with
drug-eluting stents: risk scores from PARIS. J Am
Coll Cardiol. 2016;67(19):2224-2234. doi:10.1016/j.
jacc.2016.02.064
30. Urban P, Meredith IT, Abizaid A, et al; LEADERS
FREE Investigators. Polymer-free drug-coated
coronary stents in patients at high bleeding risk.
N Engl J Med. 2015;373(21):2038-2047. doi:10.
1056/NEJMoa1503943
31. Vranckx P, Valgimigli M, Jüni P, et al; GLOBAL
LEADERS Investigators. Ticagrelor plus aspirin for 1
month, followed by ticagrelor monotherapy for 23
months vs aspirin plus clopidogrel or ticagrelor for
12 months, followed by aspirin monotherapy for 12
months after implantation of a drug-eluting stent:
a multicentre, open-label, randomised superiority
trial. Lancet. 2018;392(10151):940-949. doi:10.
1016/S0140-6736(18)31858-0
32. Bonaca MP, Bhatt DL, Cohen M, et al;
PEGASUS-TIMI 54 Steering Committee and
Investigators. Long-term use of ticagrelor in
patients with prior myocardial infarction. N Engl J
Med. 2015;372(19):1791-1800. doi:10.1056/
NEJMoa1500857
33. Eikelboom JW, Connolly SJ, Bosch J, et al;
COMPASS Investigators. Rivaroxaban with or
without aspirin in stable cardiovascular disease.
N Engl J Med. 2017;377(14):1319-1330. doi:10.1056/
NEJMoa1709118
34. Garcia-Garcia HM, McFadden EP, Farb A, et al;
Academic Research Consortium. Standardized end
point definitions for coronary intervention trials:
the Academic Research Consortium-2 consensus
document. Circulation. 2018;137(24):2635-2650.
35. LaRosa JC, Grundy SM, Waters DD, et al;
Treating to New Targets Investigators. Intensive
lipid lowering with atorvastatin in patients with
stable coronary disease. N Engl J Med. 2005;352
(14):1425-1435. doi:10.1056/NEJMoa050461
36. Onuma Y, Kimura T, Räber L, et al;
Bern-Rotterdam and j-Cypher Registries.
Differences in coronary risk factors, procedural
characteristics, mortality and stent thrombosis
between two all-comers percutaneous coronary
intervention registries from Europe and Japan:
a patient-level data analysis of the Bern-Rotterdam
and j-Cypher registries. EuroIntervention. 2015;11
(5):533-540. doi:10.4244/EIJY14M06_09

Stopdapt 2 randomized clinical trial

More Related Content

What's hot (20)

Similar to Stopdapt 2 randomized clinical trial (20)

More from https://aiimsbhubaneswar.nic.in/ (20)

Recently uploaded (20)

Stopdapt 2 randomized clinical trial